Journal of Inflammation Research

Journal of Inflammation Research 由 Dove Medical Press 出版，属中科院医学大类（2025 升级版3区）。按 OpenAlex 近年发文统计，该刊主要发表 Inflammatory Biomarkers in Disease Prognosis、Ferroptosis and cancer prognosis、Inflammasome and immune disorders 等主题的论文，这 3 个主题约占 27.9%，主导子领域为 Immunology。（根据 OpenAlex 主题统计与中科院分区数据生成）

Editor-in-Chief: Professor Ning Quan The Journal of Inflammation Research is an international, peer-reviewed, open access journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation. Specific topics covered by the journal include: acute/chronic inflammation mediators of inflammation cellular processes molecular mechanisms neuroimmune mechanisms pharmacology and novel anti-inflammatory drugs clinical conditions involving inflammation The journal welcomes the following article types on all aspects of inflammation unless otherwise stated below. The journal does not consider case reports except in circumstances where they make a valuable contribution to the literature. Protocols of prospective studies need to be accompanied by detailed and original video demonstrations of the proposed research. Bibliometric studies are welcome but must add significantly to the body of knowledge about inflammation research, and meta-analyses are not considered for publication. When considering submission of a paper utilizing publicly available data (e.g. SEER/GWAS/TCGA/GEO/Vigibase etc.), authors should ensure that such studies add significantly to the body of knowledge about a specific disease or relevant phenotype and that they are validated using the authors’ own data through replication in an independent sample set and functional follow-up. Bioinformatics studies should also conform to these criteria. Inflammatory index submissions (including Systemic Immune-Inflammation Index (SII) and Systemic Inflammatory Response Index (SIRI)) require a multicentre cohort or a separate independent validation cohort to confirm the reproducibility of the index's predictive ability. Studies using natural product extracts/decoctions will only be considered if the active compound(s) has been adequately identified and validated. While it is often not possible to identify the “one and only active compound” from an extract or decoction, efforts should be made to provide key insights into the active ingredient(s). Authors should consider and discuss the possibility that several active compounds exhibit a synergistic effect and, thus, the mixture is more than the sum of the effects of its purified ingredients. The journal welcomes submissions to the following sections: Autoimmunity and Inflammation Cardiovascular Inflammation Dermatological Inflammation Diabetes and Inflammation Gastrointestinal Inflammation Liver and Gall Bladder I

摘自期刊官网 Aims & Scope

研究方向（LetPub）：Immunology and Microbiology-Immunology

主编 Ning Quan出版商官网

编委会国家分布：中国大陆 40 位（约 25%）；主要国家 中国 40、美国 37、土耳其 9、印度 8、英国 7（共 161 位编委标注了国家） 编委会 ↗出版商官网 · 2026-09-29

中科院期刊分区表

期刊官网公布的 JCR / CiteScore 分区

• JCR Q2 · 最佳分区 · 2025 年度
• CiteScore Q2 · 2025 年度

出版商自述数据，JCR 以 Clarivate、CiteScore 以 Scopus 公布为准；与中科院分区是不同体系。出版商官网

数据库收录

SCIEScopusDOAJLetPub

国际期刊预警名单：各版本均未列入LetPub

期刊官网自述收录

PubMed出版商官网

期刊官网列出的收录清单，未与各数据库逐一核对；Web of Science 各子库以上方记录为准。

不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。

影响力指标

影响因子

4.62LetPub · 2026-09-13

影响因子（出版商公布） 2025

5.1出版商官网 · 2026-09-29

五年影响因子（出版商公布）

5.6出版商官网 · 2026-09-29

CiteScore 2026-06

5.6LetPub · 2026-09-13

CiteScore（出版商公布） 2025

1.03出版商官网 · 2026-09-29

SJR 2026-06

1.17LetPub · 2026-09-13

SNIP 2026-06

1.03LetPub · 2026-09-13

h-index

84OpenAlex · 2026-10-01

i10-index

1,585OpenAlex · 2026-10-01

两年平均被引

4.51OpenAlex · 2026-10-01

自引率

4.3%LetPub · 2026-09-13

Gold OA 文章占比

99.24%LetPub · 2026-09-13

发文规模

年文章数

1,137LetPub · 2026-09-13

年下载量（出版商公布）

356,552出版商官网 · 2026-09-29

不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。

其他来源

平均审稿速度（社区反馈）

16 WeeksLetPub · 2026-09-13

录用率（出版商公布）

8%出版商官网 · 2026-09-29

编辑初审决定

35 天出版商官网 · 2026-09-29

投稿到发表（期刊自报）

约 16 周DOAJ · 2026-10-11

评审方式

单盲同行评审DOAJ

社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。

• APC 费用说明 ↗DOAJ
• 费用减免政策 ↗DOAJ
• 开放获取声明 ↗DOAJ
• 许可与版权 ↗DOAJ

费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。

摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。

出版商

Dove Medical Press

出版国家或地区

NEW ZEALAND

出版语言

English

ISSN

1178-7031

官方链接

• 期刊主页 ↗DOAJ
• 作者指南 ↗LetPub
• Aims & Scope ↗LetPub
• 专刊 / 特刊征稿 ↗出版商官网
• APC 费用说明 ↗DOAJ
• 费用减免政策 ↗DOAJ
• 开放获取声明 ↗DOAJ
• 许可与版权 ↗DOAJ
• 评审流程 ↗LetPub
• 编委会 ↗LetPub
• 查重政策 ↗DOAJ